Sugi Predict

Sugi Predict / Targets / MYLK4

MYLK4

Myosin light chain kinase family member 4 · Q86YV6 · MYLK4 on Sugi Atlas →

6,033 patent compounds predicted against MYLK4, 4,542 high-confidence (nearest known ligand ≥ 0.5)

Top predicted compounds (top 20 by supporting neighbours, then confidence)

CompoundConfidenceSupporting neighbours
SCHEMBL433250 SCHEMBL433250 0.44 5/20
SCHEMBL1253110 SCHEMBL1253110 0.64 3/20
SCHEMBL435104 SCHEMBL435104 0.46 3/20
SCHEMBL558622 SCHEMBL558622 0.46 3/20
SCHEMBL558696 SCHEMBL558696 0.46 3/20
SCHEMBL392690 SCHEMBL392690 0.40 3/20
SCHEMBL393253 SCHEMBL393253 0.40 3/20
SCHEMBL395016 SCHEMBL395016 0.39 3/20
Bms-345541 Bms-345541 (SCHEMBL118886) 1.00 2/20
Netarsudil Netarsudil (SCHEMBL114266) 0.67 2/20
Netarsudil Netarsudil (SCHEMBL113752) 0.66 2/20
Netarsudil Netarsudil (SCHEMBL113753) 0.66 2/20
Netarsudil Netarsudil (SCHEMBL114348) 0.66 2/20
SCHEMBL226380 SCHEMBL226380 0.58 2/20
SCHEMBL112483 SCHEMBL112483 0.55 2/20
SCHEMBL435393 SCHEMBL435393 0.46 2/20
SCHEMBL20513 SCHEMBL20513 0.46 2/20
SCHEMBL435440 SCHEMBL435440 0.46 2/20
SCHEMBL1254733 SCHEMBL1254733 0.44 2/20
SCHEMBL1136845 SCHEMBL1136845 0.43 2/20

Clinical trials — most relevant to MYLK4 by text similarity (a relevance ranking, not an exhaustive list)

TrialPhaseStatus
Treatment of Preclinical Hypertrophic Cardiomyopathy With Diltiazem PHASE2/PHASE3COMPLETED
COSMIC-HF - Chronic Oral Study of Myosin Activation to Increase Contractility in Heart Failure PHASE2COMPLETED
A Phase 2 Open-label Pilot Study Evaluating MYK-461 in Subjects With Symptomatic Hypertrophic Cardiomyopathy and Left Ventricular Outflow Tract Obstruction PHASE2COMPLETED
A Study to Assess the Safety, Tolerability, Efficacy, Pharmacokinetics, and Immunogenicity of Intravenous Administration of ARGX-119 in Pediatric Participants Aged 5 to Less Than 18 Years With Spinal Muscular Atrophy PHASE2RECRUITING
Targeted Therapy With Glycogen Synthase Kinase-3 Inhibition for Arrhythmogenic Cardiomyopathy PHASE2RECRUITING
Evaluating MED2005 & Nitrostat Bioavailability PHASE1COMPLETED
Genetic Analysis of African-Americans With High Blood Pressure nanCOMPLETED
Transcutaneous Functional Magnetic Muscle Stimulation in Critically Ill nanUNKNOWN
Effect of Exercise on the Human Skeletal Muscle Phosphoproteome nanCOMPLETED
MYT1L Syndrome: a Rare Paediatric Genetic Syndrome Responsible for a Neurodevelopmental Disorder nanRECRUITING
Evaluation of Vasopressin in the Vessels of Ovarian Neoplasms nanCOMPLETED
Muscle Wasting in Cancer (MWIC) nanCOMPLETED
Congenital Muscle Disease Study of Patient and Family Reported Medical Information nanRECRUITING
A Multicenter Phenotype-Genotype Analysis of LGMD Patients in China nanENROLLING_BY_INVITATION
Pediatric Cardiomyopathy Mutation Analysis nanRECRUITING
Study of Genotype and Phenotype Characterization in Duchenne Muscular Dystrophy With Small Mutations nanUNKNOWN
Phenotypic and Genotypic Identification and Characterization of MYH9-related Constitutional Thrombocytopenia nanCOMPLETED
Nuclear Myosin VI - a Therapeutic Target in Breast Cancer nanUNKNOWN
Mapping of End Stage Renal Disease Genetic Susceptibility in African Americans by Admixture Linkage Disequilibrium nanCOMPLETED
Signs and Symptoms Associated With Molecular Defects in Genetically Inherited Heart Disease nanCOMPLETED
Molecular Mechanisms of Exercise Benefits to Insulin Resistant People nanCOMPLETED
Effects of Whole Body Vibration and Resistance Exercise on Carotis Intima Media and Muscle Architecture in Hypertension nanCOMPLETED
Phenotype - Genotype Correlation in a Sample of Egyptian Patients With Congenital Myopathies and Congenital Muscular Dystrophies nanRECRUITING
Muscle Tissue Bank for Muscular Dystrophy nanCOMPLETED
Recurrent Acute Myocarditis Registry nanUNKNOWN
Characteristics of Nondystrophic Myotonias nanCOMPLETED
Predictive Factors and Consequences of Myocardial Fibrosis in Hypertrophic Cardiomyopathy nanUNKNOWN
Natural History Study for Patients With Nemaline Myopathy in Belgium nanNOT_YET_RECRUITING
The Muscle in Cerebral Palsy; Sarcomere Length in Vivo and Microscopic Characterization of Biopsies. nanRECRUITING
New Diagnostic Strategy in Hypertrophic Cardiomyopathy nanUNKNOWN

Related proteins — ESM-2 sequence neighbours (a MYLK4 binder may also engage these)

ProteinNameSimilarity
Q5SUV5 — 0.994 Q5SUV5 →
Q8VDF3 — 0.988 Q8VDF3 →
STK32A Serine/threonine-protein kinase 32A 0.986 landscape →
Q6PFQ0 — 0.984 Q6PFQ0 →
P13234 — 0.983 P13234 →
Q9JJX8 — 0.983 Q9JJX8 →
DAPK3 Death-associated protein kinase 3 0.983 landscape →
P09215 — 0.983 P09215 →
Q09136 — 0.983 Q09136 →
P24719 — 0.983 P24719 →
Q7SY49 — 0.982 Q7SY49 →
Q6GLS4 — 0.982 Q6GLS4 →
Q8BRK8 — 0.982 Q8BRK8 →
Q39030 — 0.982 Q39030 →
Q8C050 — 0.981 Q8C050 →
CAMK2D Calcium/calmodulin-dependent protein kinase type II subunit delta 0.981 landscape →
P07934 — 0.981 P07934 →
DYRK4 Dual specificity tyrosine-phosphorylation-regulated kinase 4 0.981 landscape →
RPS6KB1 Ribosomal protein S6 kinase beta-1 0.981 landscape →
PRKCD Protein kinase C delta type 0.981 landscape →
Q9NBK5 — 0.981 Q9NBK5 →
DAPK2 Death-associated protein kinase 2 0.981 landscape →
Q02111 — 0.980 Q02111 →
PRKCQ Protein kinase C theta type 0.980 landscape →
Q6TJY3 — 0.980 Q6TJY3 →
Q755C4 — 0.980 Q755C4 →
O19111 — 0.980 O19111 →
Q8BGW6 — 0.980 Q8BGW6 →
Q12706 — 0.980 Q12706 →
Q5PU49 — 0.980 Q5PU49 →